spacer
home > ebr > spring 2007 > biosensors: rapid, preparation-free measurement
PUBLICATIONS
European Biopharmaceutical Review

Biosensors: Rapid, Preparation-Free Measurement

Mark Rodgers and Paul Millner at the University of Leeds explore the role of biosensors in everything from pharmaceuticals to proteins

Blood glucose sensors are the best known biosensors, since the majority of the current commercial market is aimed at diabetics. Novel biosensors are being developed that have applications in fields as diverse as pesticide monitoring, detection of toxic agents and point-of-care medical analysis. Over the past 50 years, biosensors have evolved from electrodes with membranes holding an enzyme in place into highly accurate, compact devices for rapidly quantifying a wide range of analytes. Very few of these have yet become commercially viable, due to difficulties in producing sensors in volume with sufficient reproducibility and stability. Although there are now many types of biosensor, this article will mainly consider electrochemical biosensors. Each type of electrochemical biosensor has its own strengths and weaknesses, making them more useful for particular groups of analytes. There are also several common methods of constructing the sensing surface that confer different properties on the sensor. Careful consideration of sensor construction allows fine tuning of a biosensorís electrical and physical properties to its analyte. The current generation of biosensors are likely to undergo continued evolution before the devices become truly widespread.

Many people come into contact with biosensors on a day-to-day basis without realising the wide range of analyses now performed by these devices. The market for biosensors has been estimated at around $5 billion globally, with approximately 85 per cent of this being for sensors to monitor glucose in diabetes (1,2). High blood glucose levels account for over two million deaths each year, including 21 per cent of ischemic heart disease and 13 per cent of ischemic stroke deaths. When added to those directly attributed to diabetes itself, the number is raised to 3.16 million globally, placing it in the top five worldwide causes of death. If this figure continues to rise steadily, 300 million people are estimated to be suffering from diabetes by 2045, and the global market for glucose biosensors is likely to increase consistently for decades.

However, biosensors are more than just glucose monitors and recently, more complex biosensors have been developed to provide an alternative to traditional testing for various medical and environmental analytes, ranging from infectious diseases to organophosphate pesticides and toxins (3). They have found uses in bacterial contamination monitoring and brewing, and are being examined as tools for military use. However, the number of commercially available biosensors is still low as the refinement of such devices is a complex and slow process (4).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Mark Rodgers gained his BSc in Biochemistry with Industrial Experience at UMIST and is now researching for his PhD within the Biosensors & Biocatalysis Group at the University of Leeds. He is interested in the applications of small affinity proteins (lipocalins) as sensing elements for the electrochemical detection of low molecular weight compounds, particularly hydrophobics and odours.

Dr Paul Millner gained his BSc and PhD at the University of Leeds. Originally a Protein Chemist/Molecular Biologist working on plant cell signalling, he is now Reader in Biotechnology at the same institution. He heads the Biosensors & Biocatalysis Group, which is concerned with applications of nanotechnology and particularly affinity directed self assembling systems to those areas which are directed respectively at reagentless point-of-care type diagnostics and green chemical solutions respectively.

spacer
Mark Rodgers
spacer
spacer
spacer
Dr Paul Millner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement